Research map: Treatment Patterns, Drug Survival, and Effectiveness of Tildrakizumab Among Patients with Prior Interleukin-17 Experience in the PPD CorEvitas Psoriasis Registry

Back to the article

Papers in this map

  1. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics · Alan Menter · 2019 · 971 citations · Cited by this paper
  2. Consensus Recommendations for Management of Darier Disease: A Practical Approach · 2026 · Related
  3. Comparison of Biologics and Oral Treatments for Plaque Psoriasis · April Wang Armstrong · 2020 · 294 citations · Cited by this paper
  4. Effectiveness, Safety, and Drug Survival of Bimekizumab in Chronic Plaque Psoriasis over 2 Years: Real-World Experience from Northern Italy · 2026 · Related
  5. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry · Bruce E Strober · 2017 · 102 citations · Cited by this paper
  6. Characteristics of Dupilumab-Treated Patients with Atopic Dermatitis Over Time: A Cross-Sectional Assessment of Potential Channeling Bias upon Pediatric Label Extension · 2026 · Related
  7. Safety of selective IL ‐23p19 inhibitors for the treatment of psoriasis · Jeffrey Crowley · 2019 · 85 citations · Cited by this paper
  8. Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment · 2026 · Related
  9. An evolution in switching therapy for psoriasis patients who fail to meet treatment goals · Francisco A. Kerdel · 2015 · 79 citations · Cited by this paper
  10. JAK Inhibitor Safety in Atopic Dermatitis and Alopecia Areata: A 4.5-Year Real-World Retrospective Cohort Study · 2026 · Related
  11. Clinical Characteristics Associated With Response to Biologics in the Treatment of Psoriasis · Gustav Hjort · 2024 · 62 citations · Cited by this paper
  12. Description of the Tranquillo Phase 3 Clinical Trial Designs/Study Protocols to Assess Ritlecitinib in Adults and Adolescents with Nonsegmental Vitiligo · 2026 · Related
  13. Switching of biologics in psoriasis: Reasons and results · Hiromi Honda · 2017 · 60 citations · Cited by this paper
  14. Real-World Long-Term Effectiveness and Safety of Secukinumab in Psoriasis: Up to 7 Years of Evidence from the Italian Landscape Psoriasis (IL PSO) Multicenter Retrospective Study · 2026 · Related
  15. Effectiveness of anti‐interleukin 23 biologic drugs in psoriasis patients who failed anti‐interleukin 17 regimens. A real‐life experience · Claudio Bonifati · 2020 · 44 citations · Cited by this paper
  16. Itch, Scratching, and Sleep Mediate the Association between Disease Severity and Quality of Life in Pruritic Dermatoses: A Cross-Sectional Study · 2026 · Related
  17. Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study · Leila Motedayеn Aval · 2025 · 32 citations · Cited by this paper
  18. Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region · 2026 · Related
  19. A Retrospective Real-World Study of the Effectiveness and Tolerability of Tildrakizumab in UK Adults with Moderate-to-Severe Chronic Plaque Psoriasis · Gabrielle Becher · 2022 · 26 citations · Cited by this paper
  20. Immunobiological Therapy in Moderate-to-Severe Psoriasis: A Retrospective Cohort Study Investigating the Effects of Inadequate Therapeutic Compliance on Drug Survival · 2026 · Related
  21. Efficacy of tildrakizumab by patient demographic and disease characteristics across a phase 2b and 2 phase 3 trials in patients with moderate‐to‐severe chronic plaque psoriasis · Yves P. Poulin · 2020 · 25 citations · Cited by this paper
  22. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort · Riccardo Viola · 2024 · 14 citations · Cited by this paper
  23. Interclass Switch between IL17 and IL23 Inhibitors in Psoriasis: A Real-Life, Long-Term, Single-Center Experience · Silvia Giordano · 2023 · 13 citations · Cited by this paper
  24. Biopharmaceutical Switching in Psoriasis Treatment · Miao Zhang · 2025 · 13 citations · Cited by this paper
  25. Effectiveness and Safety of Tildrakizumab in Psoriasis Patients Who Failed Anti-IL17 Treatment: A 28-Week Real-Life Study · Matteo Megna · 2024 · 11 citations · Cited by this paper
  26. Interleukin (IL)-17 Versus IL-23 Inhibitors: Which Is Better to Treat Patients With Moderate-to-Severe Psoriasis and Mild Psoriatic Arthritis in Dermatology Clinics? · Rosario Agüero · 2023 · 8 citations · Cited by this paper
  27. Intraclass switching of interleukin-23 inhibitors in psoriasis: effectiveness, patterns and predictors of response – a retrospective multicentre study in Italy · Giacomo Caldarola · 2025 · 3 citations · Cited by this paper

Source: OpenAlex (CC0)